Everything below concerns N-terminal modification. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-15. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
特沙莫瑞林的检测通常依赖反相高效液相色谱和质谱联用。反相色谱可分离肽主峰与缺失序列、氧化产物等杂质，质谱则提供精确质量以确认身份。对于复杂基质中的定量，常采用液相色谱-串联质谱，并配合固相萃取或蛋白沉淀。生物样品中的肽易降解，因此采集和处理条件会影响结果。
稳定性研究通常考察温度、光照、湿度和 pH 对肽链的影响。冻干粉在低温避光条件下较为稳定，复溶后则需控制保存时间并避免反复冻融。肽类可能发生氧化、脱酰胺、水解和聚集，这些变化会改变色谱纯度。强制降解实验用于识别主要降解途径并验证分析方法的专属性。
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Noriega was educated first at the Escuela República de México, and later at the Instituto Nacional, a well-regarded high school in Panama City that had produced a number of nationalist political leaders. He was described as an "oddly serious child," a bookish student always neatly dressed by his godmother. During his time in the Instituto Nacional he met his older half-brother Luis Carlos Noriega Hurtado, a socialist activist and also a student at the school: Manuel had not previously met his siblings. Manuel began living with Luis, who introduced him to politics, including recruiting him into the Socialist Party's youth wing. Luis Noriega would later direct Panama's electoral tribunal. During his time in the socialist youth group, Noriega took part in protests and authored articles criticizing the U.S. presence in Panama. He is reported to have begun his association with the U.S. intelligence services at this time, providing information about the activities of his comrades. A$10.70 payment in 1955 was the first he received from the U.S. Noriega intended to become a doctor, but was unable to secure a place in the University of Panama's medical school. After graduating from the Instituto Nacional, Noriega won a scholarship to Chorrillos Military School in the Peruvian capital of Lima, with the help of Luis, who had by then received a position in the Panamanian embassy in Peru. Noriega began studying in Lima in 1958. While there, he made the acquaintance of Roberto Díaz Herrera, then studying at the Peruvian Police academy, who later became a close ally.
== Bioactivities == Salidroside was shown to improve glucose homeostasis and alleviate diabetic retinopathy in obese mice. The antioxidant, anti-inflammatory and neuroprotective effects of salidroside have also been reported.
coenocyte A multinucleate mass of cytoplasm bounded by a cell wall and resulting from continuous cytoplasmic growth and repeated nuclear division without cytokinesis, found in some species of algae and fungi, e.g. Vaucheria and Physarum.
Sources: en.wikipedia.org
In March 2002, Yorkshire merged with Tricon Global Restaurants to form Yum! Brands. A few weeks later, Malaysian company KUB took over the franchises in Southeast Asia, aiming to restore its prestige in Malaysia alone and increasing its market share. Subsequently, in January 2003, Yum! announced that A&W and Long John Silver's would move their operational base from Lexington to Louisville, as operating the chains from Lexington was considered "impractical and cost-inefficient", preferring to operate all of its chains from Louisville. Under Yum's management, A&W added franchises with a nostalgic look and modern technology. They have a carhop design with drive-thrus, and some have picnic tables. The chain didn't seek to compete against McDonald's, instead preferring to carve up its own niche. 2004 saw the return of the Papa Burger brand at a restaurant in Dayton - the Burger Family brand originally retired in the United States in the 1980s, being replaced by the Deluxe Burgers - and was the only name of the old line that was reinstated, with the other burgers having new names. In September 2001 the Singapore branch was taken over by KUB, who also oversaw the restaurants in Malaysia. At the time of takeover, it had twelve restaurants, but by November 2002, the number had dwindled to eight. Its restaurants had already been downgraded: the Ang Mo Kio restaurant shut down, the Tampines restaurant refused to repair its air conditioning systems, and cable TV was switched off in all outlets. Food sales had decreased by about 5-12%.
Historically, the birth rate of teenagers peaked in the late 1950s and early 1960s. However, at that time, most teenage parents were married. In the early twenty-first century, nine in ten births to the age group 15-19 are to unmarried mothers. Social norms have changed; it is now not unusual for teenagers to delay or avoid sexual intercourse altogether. Younger teenagers are more likely to practice abstinence than their older counterparts. A report published by the Center for Disease Control and Prevention (CDC) in early 2018 found the number of high school students who have had sex fell from 47% in 2005 down to 41% in 2015, with the most dramatic drop taking place between 2013 and 2015. On top of that, among never-married teens who have had sex, overwhelming majorities reported they used contraception the first time they did it. There are a few reasons for this. First, Millennials and Generation Z are more focused on the consequences of sex than their predecessors were. Second, there has been growing concern over unwanted sexual advances, especially in the wake of the Me-too movement. Writing for The Spectator, Douglas Murray dubbed this the "sexual counter-revolution." Third, as a consequence of the precarious contemporary economy, young adults today are more likely to be living with their parents rather than on their own, with a romantic partner, or a spouse. A 2016 analysis by the CDC discovered that teenage birthrates nosedived between 1991, when they reached a crisis point, and 2014, when they dropped by 60%, a record low.
== Professional organizations for clinical data management == International Network of Clinical Data Management Associations (INCDMA) aims at the promotion of collaboration among clinical data management groups around the world. It is an international forum for discussion of and feedback on current topics of relevance to the discipline of CDM. It is composed of members the boards of the SCDM, ACDM, DMB (France), PSDM (The Netherlands) who participate in the INCDMA proceedings and funding. It also regroups DM leaders and subject matter experts from Europe, North America, Israel, Japan, China and Australia. The Association for Clinical Data Management (ACDM) is a global organization founded in 1987 and is Empowering Excellence in Clinical Data Management. The ACDM represents a vibrant community of dedicated clinical research professionals who are passionate about enhancing the drug development process through fostering an environment that encourages continuous learning and the practical application of modern Clinical Data Management practices. With over 35 years of service to the data management community, the ACDM's unwavering commitment is to provide clear and effective platforms for its members to network, share experiences, and stay abreast of the latest regulations and standards in Clinical Data Management. Along with supporting members on their professional development journeys, offering opportunities to gain the skills and insights needed to excel in their careers and shape the future of data management.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.